Statistics from Altmetric.com
The prevalence of anaemia ranges from 20% to 40% in patients with coronary heart disease (CHD) and is nearly 50% in patients with chronic heart failure (CHF). Anaemia is an independent predictor of poor clinical outcomes in patients with heart disease.1 ,2 Targeting anaemia to improve clinical outcomes is therefore a logical inference, with recent interest being largely driven by trials evaluating erythropoietin stimulating agents (ESAs) and one trial of intravenous iron therapy in CHF. Although recently reported Reduction of Events with Darbepoetin Alfa in Heart Failure (RED-HF) trial demonstrated no benefit of darbepoetin in CHF,3 clinical equipoise exists with …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.